Associate Professor, Internal Medicine and Developmental Biology, UT Southwestern Medical Center
Oncology
Dr. James B. Brugarolas, MD
|
|
Give Review
James Brugarolas practices Oncology. He received 10 awards: "Elected to the American Society for Clinical Investigation", "CMS Meaningful Use Stage 1 Certification", "Individual Investigator Research Award", "Research Scholar Award", "Basil OConnor Research Award", "Clinical Scientist Development Award", "V Scholar Award", "Virginia Murchison Linthicum Endowed Scholar in Biomedical Research", "Young Investigator Award" and "Claudia Adams Barr Award for Innovative Basic Cancer Research". James Brugarolas is also a published doctor. He has 32 publication published. The most recent publication is: Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Loss of DAB2IP in RCC Cells enhances their growth and resistance to mTOR-targeted therapies.
- Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments.
- BAP1 loss defines a new class of renal cell Carcinoma.
- Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell Carcinoma-specific death.
- Stereotactic Radiation Therapy of Renal Cancer Inferior Vena Cava Tumor Thrombus.
- Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
- Bap1 is essential for kidney function and cooperates with Vhl in Renal tumorigenesis.
- Spectrum of diverse genomic alterations define non-clear cell renal Carcinoma subtypes.
- Establishing a human renal cell Carcinoma tumorgraft platform for preclinical drug testing.
- Molecular Genetics of Clear-Cell Renal Cell Carcinoma.
- REDD1/DDIT4-independent mTORC1 Inhibition and Apoptosis by Glucocorticoids in Thymocytes.
- Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell Carcinoma.
- Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications.
- Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1.
- BAP1 immunohistochemistry in a multi-institutional cohort predicts outcomes in patients with clear cell renal cell Carcinoma.
- Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.
- Cooperation and Antagonism among Cancer Genes: The Renal Cancer Paradigm.
- Germline BAP1 mutation predisposes to familial clear-cell renal cell Carcinoma.
- Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell Carcinoma: a retrospective analysis with independent validation.
- Metabolism of kidney Cancer: from the lab to clinical practice.
- Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes.
- Prolonged Survival of a Patient With Papillary Renal Cell Carcinoma and Brain Metastases Using Pazopanib.
- State of the science: an update on renal cell Carcinoma.
- A validated tumorgraft model reveals activity of dovitinib against renal cell Carcinoma.
- TFEB, a novel mTORC1 effector implicated in lysosome biogenesis, endocytosis and autophagy.
- Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell Carcinoma type 2.
- Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor.
- Interplay between pVHL and mTORC1 pathways in clear-cell renal cell Carcinoma.
- Regulation of TFEB and V-ATPases by mTORC1.
- TSC2 regulates VEGF through mTOR-dependent and -independent pathways.
- PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma.
Schools
Universidad De Navarra Facultad De Medicina
Duke University Hospital Center
Dana Faber Cancer Institute
Conditions Treated
- AdRenal Gland Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected to the American Society for Clinical Investigation
- CMS Meaningful Use Stage 1 Certification
- Individual Investigator Research Award
- Research Scholar Award
- Basil O’Connor Research Award
- Clinical Scientist Development Award
- V Scholar Award
- Virginia Murchison Linthicum Endowed Scholar in Biomedical Research
- Young Investigator Award
- Claudia Adams Barr Award for Innovative Basic Cancer Research
Education
-
Duke University Hospital -
Universidad de Navarra Faculty of Medicine
Hospital
-
University of Texas Southwestern Medical Center
Drug Facts
| NPI NUMBER | 1629091723 | |
| NPPES Provider LastName | BRUGAROLAS | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 753907208 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 190.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 5.79 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629091723 |
| Last Name Of The Provider | BRUGAROLAS |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
Dr. Atisha P. Manhas, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry D. Anderson Jr., MD |
|
|
Dr. Maria I. Juarez, MD |
|
|
Dr. Cynthia R. Osborne, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James K. Willson Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen E. Jones, MD |
|
|
Dr. Emil T. Kuriakose, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy S. Paulson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar A. Santa-Maria, MD |